Repurposing mitochondria-targeted therapeutics for kidney diseases

Austin D. Thompson; Paul Victor Santiago Raj; Natalie E. Scholpa; Rick G. Schnellmann

doi:10.1016/j.kint.2024.12.020

journal article Open Access Apr 01, 2025

Repurposing mitochondria-targeted therapeutics for kidney diseases

Austin D. Thompson Paul Victor Santiago Raj Natalie E. Scholpa Rick G. Schnellmann

Kidney International Vol. 107 No. 4 pp. 617-627 · Elsevier BV

View at Publisher Save 10.1016/j.kint.2024.12.020

Topics

No keywords indexed for this article. Browse by subject →

References

68

[1]

Epidemiology of chronic kidney disease: an update 2022

Csaba P. Kovesdy

Kidney International Supplements 2022 10.1016/j.kisu.2021.11.003

[2]

A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases

Kitty J. Jager, Csaba Kovesdy, Robyn Langham et al.

Kidney International 2019 10.1016/j.kint.2019.07.012

[3]

Rhee "Spotlight on CKD deaths—increasing mortality worldwide" Nat Rev Nephrol (2015) 10.1038/nrneph.2015.25

[4]

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Boris Bikbov, Caroline A Purcell, Andrew S Levey et al.

The Lancet 2020 10.1016/s0140-6736(20)30045-3

[5]

Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Norbert H. Lameire, Adeera Levin, John A. Kellum et al.

Kidney International 2021 10.1016/j.kint.2021.06.028

[6]

Kellum "Conceptual advances and evolving terminology in acute kidney disease" Nat Rev Nephrol (2021) 10.1038/s41581-021-00410-w

[7]

Ferenbach "Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD" Nat Rev Nephrol (2015) 10.1038/nrneph.2015.3

[8]

Jiménez-Uribe "Promising therapeutic strategies targeting mitochondria in kidney diseases: from small molecules to whole mitochondria" Future Pharmacol (2022) 10.3390/futurepharmacol2030017

[9]

Tanriover "The mitochondrion: a promising target for kidney disease" Pharmaceutics (2023) 10.3390/pharmaceutics15020570

[10]

Zhang "The role of mitochondria in acute kidney injury and chronic kidney disease and its therapeutic potential" Int J Mol Sci (2021)

[11]

Panchapakesan "Drug repurposing in kidney disease" Kidney Int (2018) 10.1016/j.kint.2017.12.026

[12]

Burgart "Synthesis of 4-aminopyrazol-5-ols as edaravone analogs and their antioxidant activity" Molecules (2022) 10.3390/molecules27227722

[13]

Varatharajan "Effect of edaravone in diabetes mellitus-induced nephropathy in rats" Korean J Physiol Pharmacol (2016) 10.4196/kjpp.2016.20.4.333

[14]

Montes-Rivera "Effect of (-)-epicatechin on the modulation of progression markers of chronic renal damage in a 5/6 nephrectomy experimental model" Heliyon (2019) 10.1016/j.heliyon.2019.e01512

[15]

Tain "Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat" Am J Physiol Renal Physiol (2007) 10.1152/ajprenal.00260.2006

[16]

Park "Paricalcitol attenuates cyclosporine-induced kidney injury in rats" Kidney Int (2010) 10.1038/ki.2010.69

[17]

Mousleh "The preventive role of pioglitazone in glycerol-induced acute kidney injury in rats during two different treatment periods" Iran J Med Sci (2018)

[18]

Hurtado "Lasmiditan promotes recovery from acute kidney injury through induction of mitochondrial biogenesis" Am J Physiol. Renal Physiol (2023) 10.1152/ajprenal.00249.2022

[19]

Arif "β(2)-Adrenergic receptor agonists as a treatment for diabetic kidney disease" Am J Physiol Renal Physiol (2024) 10.1152/ajprenal.00254.2023

[20]

Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury

Ehtesham Arif, Ashish K. Solanki, Pankaj Srivastava et al.

Kidney International 2019 10.1016/j.kint.2019.03.023

[21]

Choi "Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats" Am J Physiol Renal Physiol (2009) 10.1152/ajprenal.90609.2008

[22]

Tomita "The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease" Physiol Rep (2020) 10.14814/phy2.14556

[23]

Tampe "Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression" Kidney Int (2017) 10.1016/j.kint.2016.07.042

[24]

Horino "Effects of topiroxostat in hyperuricemic patients with chronic kidney disease" Clin Exp Nephrol (2018) 10.1007/s10157-017-1452-3

[25]

Zhang "Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin" Nefrologia (Engl Ed) (2021) 10.1016/j.nefroe.2021.11.007

[26]

Lakhia "PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice" Am J Physiol Renal Physiol (2018) 10.1152/ajprenal.00352.2017

[27]

Aomura "Pemafibrate protects against fatty acid-induced nephropathy by maintaining renal fatty acid metabolism" Metabolites (2021) 10.3390/metabo11060372

[28]

Horinouchi "Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease" Life Sci (2023) 10.1016/j.lfs.2023.121590

[29]

Oey "Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis" Exp Biol Med (Maywood) (2018) 10.1177/1535370218759313

[30]

Yang "Dimethyl fumarate prevents ferroptosis to attenuate acute kidney injury by acting on NRF2" Clin Transl Med (2021) 10.1002/ctm2.382

[31]

Oh "Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling" PLoS One (2012) 10.1371/journal.pone.0045870

[32]

Lynch "Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study)" Ann Neurol (2021) 10.1002/ana.25934

[33]

Feng "Mitochondria as an important target of metformin: the mechanism of action, toxic and side effects, and new therapeutic applications" Pharmacol Res (2022) 10.1016/j.phrs.2022.106114

[34]

Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway

Xiao-cui Chen, Dan Wu, Hong-luan Wu et al.

Lupus Science & Medicine 2022 10.1136/lupus-2021-000611

[35]

Yi "Metformin attenuates renal fibrosis in a mouse model of adenine-induced renal injury through inhibiting TGF-β1 signaling pathways" Front Cell Dev Biol (2021) 10.3389/fcell.2021.603802

[36]

Zhang "Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway" FASEB J (2020) 10.1096/fj.201903038r

[37]

Yang "SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease" J Diabetes Complications (2024) 10.1016/j.jdiacomp.2023.108652

[38]

Prasad "Sodium-glucose cotransporter-2 inhibitor suppresses endoplasmic reticulum stress and oxidative stress in diabetic nephropathy through Nrf2 signaling: a clinical and experimental study" J Clin Pharmacol (2024) 10.1002/jcph.2465

[39]

Zeng "Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage" Front Pharmacol (2023) 10.3389/fphar.2023.1095487

[40]

Chavez "Mitochondrial protein interaction landscape of SS-31" Proc Natl Acad Sci U S A (2020) 10.1073/pnas.2002250117

[41]

Zhu "SS-31, a mitochondria-targeting peptide, ameliorates kidney disease" Oxid Med Cell Longev (2022) 10.1155/2022/1295509

[42]

Victor "Crosstalk between endoplasmic reticulum stress and oxidative stress in the progression of diabetic nephropathy" Cell Stress Chaperones (2021) 10.1007/s12192-020-01176-z

[43]

Tahara "A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation" Transplantation (2005) 10.1097/01.tp.0000165092.07375.c9

[44]

Williams "Kidney-targeted redox scavenger therapy prevents cisplatin-induced acute kidney injury" Front Pharmacol (2021)

[45]

Shaki "The effect of epicatechin on oxidative stress and mitochondrial damage induced by homocycteine using isolated rat hippocampus mitochondria" Res Pharm Sci (2017) 10.4103/1735-5362.202450

[46]

Festa "Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney" Nat Commun (2018) 10.1038/s41467-017-02536-7

[47]

Luciani "Impaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency" Nat Commun (2020) 10.1038/s41467-020-14729-8

[48]

Wang "Paricalcitol ameliorates acute kidney injury in mice by suppressing oxidative stress and inflammation via Nrf2/HO-1 signaling" Int J Mol Sci (2023) 10.3390/ijms24020969

[49]

Mune "Vitamin E supplementation improves high-densitiy lipoprotein and endothelial functions in end-stage kidney disease patients undergoing hemodialysis" Clin Nephrol (2018) 10.5414/cn109197

[50]

Bhargava "Mitochondrial energetics in the kidney" Nat Rev Nephrol (2017) 10.1038/nrneph.2017.107

Showing 50 of 68 references

Metrics

12

Citations

68

References

Details

Published: Apr 01, 2025
Vol/Issue: 107(4)
Pages: 617-627
License: View

Authors

A

Austin D. Thompson

P

Paul Victor Santiago Raj

Medical University of South Carolina Charleston South Carolina

Funding

National Institutes of Health

National Institute of Environmental Health Sciences Award: T32-5T32ES007091-40

Cite This Article

Austin D. Thompson, Paul Victor Santiago Raj, Natalie E. Scholpa, et al. (2025). Repurposing mitochondria-targeted therapeutics for kidney diseases. Kidney International, 107(4), 617-627. https://doi.org/10.1016/j.kint.2024.12.020

Repurposing mitochondria-targeted therapeutics for kidney diseases

You May Also Like